logo-loader
viewRhythm Biosciences Ltd

Rhythm Biosciences signs The Alfred Hospital for ColoSTAT clinical test

ColoSTAT has the potential to play an important role in reducing morbidity and mortality rates associated with colorectal cancer.

1561527428_clintrial2.jpg
Rhythm's lead product ColoSTAT is a low-cost blood test for the early detection of bowel cancer

Rhythm Biosciences Ltd (ASX:RHY) has signed The Alfred Hospital in Melbourne as its third clinical trial site for ColoSTAT®, the lifesaving blood test for the early detection of colorectal cancer.

Associate Professor and Head of Endoscopy at the hospital, Gregor Brown, has been appointed as the site’s principal investigator for the trial.

Brown is well recognised for his research into improving colonoscopy techniques including polyp removal during colonoscopy and balloon enteroscopy as well for the development of new treatments for coeliac and inflammatory bowel diseases.

Shares are up more than 6% today to 17.5 cents.

“Deep expertise in colonoscopic research”

Rhythm chief executive officer Glenn Gilbert said: “The Alfred Hospital has a long history of supporting clinical trials and a deep expertise in colonoscopic research.

“Working with The Alfred adds to the credibility of this clinical trial and we look forward to this collaboration and ultimately the results.”

Recruitment for the trial is expected to reach around 1,000 patients and will be completed at the end of 2019.

The trial will form a key component for both CE Mark & TGA registration as well as approval to market ColoSTAT in Australia and Europe in 2020.

READ: Rhythm Bioscience welcomes new ColoSTAT trial member in Monash Health

The company continues to work with global parties on the most effective assay development, optimisation and clinical utility of the reagents that will form the core components to the final ColoSTAT test.

Rhythm Bioscience also expects to welcome further hospitals to the ColoSTAT trial in the coming months.

Quick facts: Rhythm Biosciences Ltd

Price: 0.17 AUD

ASX:RHY
Market: ASX
Market Cap: $17.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Parkway Minerals focuses on technology after recent...

Parkway Minerals NL (ASX:PWN) executive director Bahay Ozcakmak updates Proactive on its recent acquisition of unlisted company Consolidated Potash Corporation, which gives Parkway an advanced stage potash project and ownership of an innovative brine processing technology. The executive...

22 hours ago

2 min read